Sinobioway Medicine(SZ:002581) Xin Lang Cai Jing·2026-02-03 06:12Group 1 - The core point of the article is that ST Weiming (SZ002581) reached its daily limit with a price of 7.55 yuan, reflecting a 5.01% increase and a total market capitalization of 4.981 billion yuan [1] - The stock price surge is attributed to several factors including the approval of the innovative drug SMR001 eye drops for clinical phase III, which targets a 18 billion yuan dry eye market and showcases the company's technological strength in the pharmaceutical field [2] - The company's operational status has improved, with the 2025 annual report indicating a reduction in losses to between 90 million and 55 million yuan, a year-on-year decrease of 34.46% to 59.95%, enhancing market expectations for future profitability [2] Group 2 - A subsidiary of the company has obtained a pharmaceutical operating license, which enhances the pharmaceutical supply chain layout and includes a 6,000 square meter modern logistics facility that can improve operational efficiency [2] - Although specific funding data for the day is not available, the improvement in the company's fundamentals is likely to attract investor attention [2] - There is no technical analysis provided, but the positive operational changes are expected to influence investor expectations regarding the stock price trend [2]